How Investors May Respond To Supernus Pharmaceuticals (SUPN) FDA Approval For ONAPGO

Simply Wall St.

Yesterday

Supernus Pharmaceuticals recently received FDA approval for ONAPGO, a treatment for motor fluctuations in Parkinson's disease, expanding its central nervous system portfolio. This new approval adds ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2674495817"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2674495817\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2674495817?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","is_english":true,"pubTime":"2026-10-11 18:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2674495817","market":"hk","top_or_hot":-1,"title":"How Investors May Respond To Supernus Pharmaceuticals (SUPN) FDA Approval For ONAPGO","media":"Simply Wall St.","content":"<div>\n<p>Supernus Pharmaceuticals recently received FDA approval for ONAPGO, a treatment for motor fluctuations in Parkinson's disease, expanding its central nervous system portfolio. This new approval adds ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/how-investors-may-respond-to-supernus-pharmaceuticals-supn-f\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors May Respond To Supernus Pharmaceuticals (SUPN) FDA Approval For ONAPGO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors May Respond To Supernus Pharmaceuticals (SUPN) FDA Approval For ONAPGO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-11 18:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/how-investors-may-respond-to-supernus-pharmaceuticals-supn-f><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Supernus Pharmaceuticals recently received FDA approval for ONAPGO, a treatment for motor fluctuations in Parkinson's disease, expanding its central nervous system portfolio. This new approval adds ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/how-investors-may-respond-to-supernus-pharmaceuticals-supn-f\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SUPN","symbol_name":"Supernus Pharmaceuticals","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/how-investors-may-respond-to-supernus-pharmaceuticals-supn-f","article_id":"2674495817","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/how-investors-may-respond-to-supernus-pharmaceuticals-supn-f","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2674495817","pubTimestamp":1791714796,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Supernus Pharmaceuticals recently received FDA approval for ONAPGO, a treatment for motor fluctuations in Parkinson's disease, expanding its central nervous system portfolio.\nThis new approval adds another commercial product alongside Qelbree, GOCOVRI and Oxtellar XR, which may influence how investors view Supernus Pharmaceuticals' earning power and product diversity.\nWe will now assess how Supernus Pharmaceuticals' investment narrative could evolve in light of the new ONAPGO approval in...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SUPN":"Supernus Pharmaceuticals","BK4007":"制药","BK4211":"区域性银行","ISBC":"投资者银行","BK4588":"碎股","BK4585":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion"},"translate_title":"投资者如何应对 Supernus Pharmaceuticals (SUPN) FDA 批准 ONAPGO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SUPN":1.5,"LABU":1.5,"ISBC":1.5},"content_text":"Supernus Pharmaceuticals recently received FDA approval for ONAPGO, a treatment for motor fluctuations in Parkinson's disease, expanding its central nervous system portfolio. This new approval adds another commercial product alongside Qelbree, GOCOVRI and Oxtellar XR, which may influence how investors view Supernus Pharmaceuticals' earning power and product diversity. We will now assess how Supernus Pharmaceuticals' investment narrative could evolve in light of the new ONAPGO approval in Parkinson's disease.  Spot other central nervous system players that could be building similar momentum by scanning our curated list of 34 healthcare AI stocks aligned with breakthroughs such as Supernus Pharmaceuticals' ONAPGO approval in Parkinson's disease.\nAdvertisementSupernus Pharmaceuticals Investment Narrative Recap To own Supernus Pharmaceuticals, you need to believe this CNS focused business can turn a broad portfolio into cleaner earnings over time. The near term story still hinges on execution. The ONAPGO approval deepens its Parkinson’s disease presence and may support better use of the existing commercial footprint rather than changing the overall thesis overnight. The biggest swing factor remains whether management can translate prescription momentum in Qelbree, GOCOVRI and now ONAPGO into sustainably higher revenue while managing costs. Key risk sits on the other side of that equation. Integration complexity, cash obligations and ongoing R&D spend could keep profitability pressured if uptake disappoints. In that context, the ONAPGO approval looks operationally important because it adds another Parkinson’s disease product to an already CNS heavy range. More touchpoints with neurologists can make sales efforts more efficient, especially when layered on top of GOCOVRI and APOKYN. For you as a shareholder, this is about depth in a single specialty rather than sheer product count. ONAPGO also interacts directly with the main catalysts analysts have been watching. A fuller Parkinson’s disease suite can support the aim of lifting revenue from US$830.4 million while working toward profitability after the recent loss of US$109.9 million. The risk is straightforward. If prescriptions and reimbursement do not build as expected, fixed selling expenses and R&D for programs like SPN 820 and SPN 817 remain harder to absorb. Supernus Pharmaceuticals' narrative projects US$1.8b revenue and US$176.7 million earnings by 2029. This implies 28.2% yearly revenue growth and an earnings swing of about US$286.6 million from the current loss of US$109.9 million. Uncover why Supernus Pharmaceuticals' fair value indicates a 45% potential upside to its current price, which could be realized more quickly than many investors expect. NasdaqGM:SUPN 1-Year Stock Price Chart Exploring Other Perspectives Two fair value views from the Simply Wall St Community span roughly US$61.75 to about US$210.30 per share, so opinions on Supernus Pharmaceuticals differ widely. That is before factoring in potential catalysts such as pipeline progress, ONAPGO rollout and the planned Indivior merger. Use that spread to pressure test your own thesis. Explore another Supernus Pharmaceuticals fair value estimate, including one that suggests it could be worth just $61.75! Reach Your Own Conclusion Don't just follow the ticker; dig into the data and build a conviction that's truly your own.  A great starting point for your Supernus Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision. See our latest analysis for Supernus Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Supernus Pharmaceuticals' overall financial health at a glance.  Looking For More Investment Ideas Beyond Supernus Pharmaceuticals? Once you have formed a view on Supernus Pharmaceuticals, it can help to compare that thesis with other opportunities on the Simply Wall St Screener. Different filters surface very different types of businesses, which can sharpen how you think about risk, income and upside.  If you want potential upside with tighter risk controls, focus on companies that already score well on resilience and balance sheet strength through our 31 resilient stocks with low risk scores. For investors who care most about price paid versus underlying quality, use the valuation filters to uncover 29 high quality undervalued stocks that might deserve a closer look. If you prefer sturdier finances and fewer surprises, concentrate on companies with strong cash positions and manageable debt by running the list of solid balance sheet and fundamentals (25 results).   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}